Avidity Biosciences Announces Proposed Public Offering of Common Stock
RNA(NASDAQ:RNA) SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market...
Avidity Biosciences to Participate in Upcoming Investor Conferences
RNASAN DIEGO, Aug. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside...
Raymond James Initiates Coverage On Avidity Biosciences with Strong Buy Rating, Announces Price Target of $65
RNAAvidity Biosciences To Present Topline Data From Phase 1/2 FORTITUDE Trial Of Del-Brax In People Living With Facioscapulohumeral Muscular Dystrophy At Annual FSHD Society International Research Congress
RNAThe Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts
RNACORRECTION: Barclays Maintains Overweight on Avidity Biosciences, Raises Price Target to $59 (Firm Changed)
RNAJP Morgan Maintains Overweight on Avidity Biosciences, Raises Price Target to $59
RNAB of A Securities Maintains Buy on Avidity Biosciences, Raises Price Target to $54
RNAAvidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial
RNAAvidity shares early del-brax FSHD data showing improved mobility, strength, and safety; Phase 3 FORWARD trial now underway.
Chardan Capital Maintains Buy on Avidity Biosciences, Raises Price Target to $75
RNAAvidity Biosciences Says Accelerated Approval Regulatory Pathway In United States Is Open For Del-Brax In Treatment Of Facioscapulohumeral Muscular Dystrophy
RNAAvidity Biosciences Reports Topline Data From Dose Escalation Cohorts Of Del-Brax Phase 1/2 FORTITUDE Program In FSHD; Data Support Planned Accelerated Approval BLA Submission In H2 2026
RNAHC Wainwright & Co. Maintains Buy on Avidity Biosciences, Lowers Price Target to $68
RNAChardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target
RNAAvidity Biosciences Q1 EPS $(0.90) Beats $(0.91) Estimate, Sales $1.57M Miss $1.90M Estimate
RNA12 Analysts Assess Avidity Biosciences: What You Need To Know
RNAChardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target
RNABeyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock
RNANeedham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target
RNAAvidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran For Myotonic Dystrophy Type 1
RNAAvidity Biosciences Finalizes Enrollment In Biomarker Cohort Of Phase 1/2 FORTITUDE™ Trial For Delpacibart Braxlosiran In Individuals With Facioscapulohumeral Muscular Dystrophy
RNAForecasting The Future: 13 Analyst Projections For Avidity Biosciences
RNAHC Wainwright & Co. Reiterates Buy on Avidity Biosciences, Maintains $72 Price Target
RNAAvidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025
RNAAvidity's del-zota met key Phase 1/2 trial goals in DMD44, shows strong exon skipping, dystrophin restoration and creatine kinase reduction.
Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target
RNAHC Wainwright & Co. Reiterates Buy on Avidity Biosciences, Maintains $72 Price Target
RNAChardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target
RNAAvidity Biosciences Announced Del-Zota Topline Data From The Phase 1/2 Explore44 Trial For Duchenne Muscular Dystrophy Amenable To Exon 44 Skipping, Demonstrating Consistent, Statistically Significant Improvements In Dystrophin, Exon Skipping And Creatine
RNACitigroup Initiates Coverage On Avidity Biosciences with Buy Rating, Announces Price Target of $70
RNABMO Capital Initiates Coverage On Avidity Biosciences with Outperform Rating, Announces Price Target of $72
RNAB of A Securities Maintains Buy on Avidity Biosciences, Lowers Price Target to $48
RNAScotiabank Initiates Coverage On Avidity Biosciences with Sector Outperform Rating, Announces Price Target of $70
RNABarclays Maintains Overweight on Avidity Biosciences, Lowers Price Target to $57
RNAAvidity Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
RNAChardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target
RNAAnalyst Expectations For Avidity Biosciences's Future
RNAWhat 8 Analyst Ratings Have To Say About Avidity Biosciences
RNAHC Wainwright & Co. Initiates Coverage On Avidity Biosciences with Buy Rating, Announces Price Target of $72
RNANeedham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target
RNA